Close



Feb 7, 2024 07:00AM
Oct 31, 2023 07:00AM
Sep 14, 2023 08:31AM
Sep 14, 2023 08:30AM
Aug 1, 2023 07:00AM
May 19, 2023 08:30AM
May 19, 2023 08:30AM Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology
Feb 6, 2023 07:30AM
Dec 22, 2022 04:01PM
Dec 22, 2022 04:01PM
Mar 9, 2021 07:48AM
Apr 3, 2020 08:33AM
Apr 3, 2020 08:30AM
Feb 24, 2020 06:56AM UPDATE: William Blair Starts Neurocrine Bio. (NBIX) at Outperform
Jan 13, 2020 06:00AM
Jan 12, 2020 06:30PM
Nov 4, 2019 04:01PM
Jul 29, 2019 04:01PM
Jul 10, 2019 04:11PM
Jul 10, 2019 04:10PM
May 1, 2018 07:40AM Neurocrine Bio. (NBIX) PT Raised to $99 at Deutsche Bank
Apr 30, 2018 04:01PM
Apr 27, 2018 08:00AM
Apr 10, 2018 08:15AM
Apr 10, 2018 08:15AM
Feb 14, 2018 06:21AM
Feb 13, 2018 04:01PM
Jan 26, 2018 09:05AM Neurocrine Bio. (NBIX) PT Raised to $103 at Piper Jaffray
Jan 8, 2018 05:45AM
Jan 7, 2018 01:00PM
Nov 1, 2017 04:01PM
Oct 27, 2017 07:01AM
Oct 27, 2017 07:00AM
Aug 3, 2017 04:01PM
Jul 5, 2017 06:29AM Neurocrine Biosciences (NBIX): 3 Reasons INGREZZA Is Better Positioned Than AUSTEDO - Oppenheimer
Mar 21, 2017 09:01AM
Mar 21, 2017 08:59AM
Mar 17, 2017 07:23AM
Mar 7, 2017 06:18AM
Feb 15, 2017 07:58AM
Feb 14, 2017 04:01PM
Feb 10, 2017 06:19AM Neurocrine Biosciences (NBIX): License Deal Favorable Terms - Piper Jaffray
Jan 27, 2017 06:32AM
Jan 6, 2017 09:29AM
Jan 6, 2017 07:44AM
Jan 6, 2017 06:25AM
Jan 5, 2017 06:06PM
Jan 5, 2017 04:30PM
Jan 5, 2017 04:01PM Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia
Nov 29, 2016 04:16PM

12,335 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All